Product Program year 2025 Source: CMS Open Payments

Xofigo

Drug Oncology

NDC 50419-208-01

Open in the dashboard

General payments

$4,640,615

57,800 payments

Research payments

$46,484,395

754 payments

Through program year 2025, $4,640,615 in general payments and $46,484,395 in research payments were reported against Xofigo (Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows
Year Kind Amount Payments
2025 General $681,293 13,394
2025 Research $4,577,703 11
2024 General $501,732 11,040
2024 Research $5,930,400 45
2023 General $520,296 12,124
2023 Research $4,514,137 80
2022 General $611,780 7,024
2022 Research $9,192,553 73
2021 General $272,468 1,910
2021 Research $9,073,956 153
2020 General $683,547 3,190
2020 Research $6,699,298 146
2019 General $1,369,501 9,118
2019 Research $6,496,348 246

Breakdown

Who paid General payments · program years 2019–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $4,636,344 57,763 payments
  2. Bayer Healthcare LLC $4,272 37 payments
Top recipients General payments · program year 2025
  1. Vijay Gunuganti Medical Oncology · San Antonio, TX $89,866 13% · 58 payments
  2. Przemyslaw Twardowski Medical Oncology · Santa Monica, CA $27,459 4% · 18 payments
  3. Pedro Barata Hematology & Oncology · New Orleans, LA $23,176 3% · 7 payments
  4. Paul Dato Urology · La Mesa, CA $22,719 3% · 24 payments
  5. Matthew Rettig Hematology & Oncology · Los Angeles, CA $16,278 2% · 12 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Urology $174,944 26% · 1,480 practitioners
  2. Medical Oncology Internal Medicine $166,657 25% · 272 practitioners
  3. Hematology & Oncology Internal Medicine $96,147 14% · 1,002 practitioners
  4. Radiation Oncology Radiology $65,853 10% · 376 practitioners
  5. Nurse Practitioner, Family Nurse Practitioner $41,605 6% · 854 practitioners

The top 5 of 84 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Texas $114,364 17% · 488 recipients
  2. California $95,022 14% · 353 recipients
  3. Florida $61,677 9% · 665 recipients
  4. New York $35,993 5% · 342 recipients
  5. Louisiana $34,752 5% · 213 recipients

The top 5 of 51 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to Xofigo
Billing code Providers Services Paid by Medicare
Radium ra-223 dichloride, therapeutic, per microcurie A9606 3 11,465 $1,581,454

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

57,800 general · 754 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record